Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure

European Journal of Heart Failure

Volumn 9, Issue 6-7, 2007, Pages 594-601

  Keyhan, Golyar ^a   Chen, Shun Fu ^a   Pilote, Louise ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Congestive heart failure; Medication exposure; Sex; Survival

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SPIRONOLACTONE; WARFARIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DATA BASE; DRUG EFFICACY; DRUG USE; FEMALE; HEART FAILURE; HOSPITAL CARE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSE OF DEATH; CHRONIC DISEASE; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; QUEBEC; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34247881902     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.03.004     Document Type: Article

References (39)

1. Koelling T.M., Chen R.S., Lubwana R.N., L'Italien G.J., and Eagle K.A. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 147 (2004) 74-78
2. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure). Circulation 104 (2001) 2996-3007
3. Jessup M., and Pina I.L. It is important to examine gender differences in the epidemiology and outcome of severe heart failure?. J Thorac Cardiovasc Surg 127 (2004) 1247-1252
4. Opasich C., Cafiero M., Scherillo M., et al. The 'real' women with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail 6 (2004) 769-779
5. Stromberg A., and Martensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs 2 (2003) 7-18
6. Jong P., Gong Y., Liu P.P., Austin P.C., Lee D.C., and Tu J.V. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared to other specialists. Circulation 108 (2003) 184-191
7. Goff D.C., Pandey D.K., Chan F.A., Ortiz C., and Nichaman M.Z. Congestive heart failure in the United States - is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 160 (2000) 197-202
8. Levy A. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 15 (1999) 1277-1282
9. Hudson M., Richard H., and Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330 (2005) 1370-1373
10. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
11. Zhou Z., Rahme E., Abrahamowicz M., and Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162 (2005) 1016-1023
12. Ghali W.A., Quan H., Brant R., et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286 (2001) 1494-1497
13. Garg R., Yusuf S., and for the Collaborative Group of ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
14. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41 (2003) 1529-1538
15. Lonn E., Roccaforte R., Yi Q., et al. Effect of long-term therapy with Ramipril in high-risk women. J Am Coll Cardiol 40 (2002) 693-702
16. Schocken D.D. Epidemiology and risk factors for heart failure in the elderly. Clin Geriatr Med 16 (2000) 407-418
17. Brunner-La Rocca H.P., Buser P.T., Schindler R., et al. TIME-CHF-Investigators. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151 (2006) 949-955
18. Philbin E.F., and DiSalvo T.G. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol 82 (1998) 76-81
19. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88 (1993) 107-115
20. Kannel W.B., and Belanger A.J. Epidemiology of heart failure. Am Heart J 121 (1991) 951-957
21. Adams K.F.J., Dunlap S.H., Sueta C.A., et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 28 (1996) 1781-1788
22. Olivetti G., Giordano G., Corradi D., et al. Gender differences and aging effects on the human heart. Am J Coll Cardiol 26 (1995) 1068-1079
23. Krumholz H.M., Larsone M., and Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 72 (1993) 310-313
24. Carroll J.D., Caroll E.P., Fedman T., et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 86 (1992) 1099-1107
25. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme - cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000) 33238-33243
26. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-E9
27. Danilczyk U., Eriksson U., Crackower M.A., and Penninger J.M. A story of two ACEs. J Mol Med-JMM 81 (2003) 227-234
28. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43 (2004) 970-976
29. Crackower M.A., Sarao R., Oudit G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
30. Yagil Y., and Yagil C. Hypothesis - ACE2 modulates blood pressure in the mammalian organism. Hypertension 41 (2003) 871-873
31. Burrell L.M., Johnston C.I., Tikellis C., and Cooper M.E. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15 (2004) 166-169
32. Adams K.F., Sueta C.A., Gheorghiade M., et al. Gender differences in survival in advanced heart failure: insights from the FIRST study. Circulation 99 (1999) 1816-1821
33. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 (2004) 693-704
34. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE. Lancet 355 (2000) 1582-1587
35. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
36. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
37. Hudson M., Rahme E., Behlouli H., Sheppard R., and Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study. Eur J Heart Fail 9 (2007) 602-609
38. Aurigemma G.P. Diastolic heart failure - a common and lethal condition by any name. N Engl J Med 355 (2006) 308-310
39. Tamblyn R., and Abrahamowicz M. Drug utilization patterns. In: Armitage P., and Colton T. (Eds). Encyclopedia of biostatistics (1998), J Wiley, United Kingdom 1235-1247